

Cancer Genomics - Analysis Plan

Courtney Vaughn, Isaac Robson, Kentaro Hoffman, and John Sperger

March 19th, 2018

1 Introduction

Our group will analyze the publically available serous ovarian cancer data available through The Cancer Genome Atlas. The TCGA data includes progression-free survival time after treatment with Platinum-based. While there is no direct data on treatment regimen, ovarian cancer treatment plans are very standardized thus survival time correlates with treatment response allowing us to study the molecular basis for varying response to treatment. Given that Platinum-based chemotherapies act by damaging DNA, it is assumed that tumor cells that have better repair efficiencies. We will test this hypothesis by creating clusters of tumor samples based on DNA damage response gene expression and looking for differences in survival between the clusters.

2 Data & Pre-processing

There are 376 RNA-Seq samples in the available data for the TCGA-OV project. We will restrict the sample to only those with clinical data available.

3 Analysis Plan

3.1 Subtype Replication

Our first planned analysis is a reproduction of the hierarchical clustering analysis[2] done on the mRNA data to replicate the four subtypes identified in the initial report by the TCGA network [4]. This will show that the initial results are reproducible, and help ensure that any additional results we may discover are not due to differences in the pre-processing stage. This assumes the gene list is available somewhere. If we can't get the gene list we'll probably skip this step.

3.2 Identify gene list of DNA damage response genes

The DNA Damage Response (DDR) gene set was retrieved from the Gene Ontology Consortium. It contains 830 genes. Gene list: <http://amigo.geneontology.org/amigo/search/bioentity?q=D>

3.3 Clustering by DNA Damage Response

It is assumed that less efficient DNA damage repair will correlate with better outcomes for patients. We will test this hypothesis by exploring the difference in treatment response between tumors cluster by DDR gene expression patterns. We will use differential expression of the 830 DDR genes to create clusters. We will first create a hierarchical clustering as an exploratory analysis, and then will use consensus clustering to select the final number of clusters [3].

3.4 Mining differential correlation

Differential Correlation Mining (DCM) is a method developed by Kelly Bodwin, Kai Zhang, and Andrew Nobel for identifying sets of variables where the average pairwise correlation between variables in a set is higher under one sample condition than the other [1]. We will split the mRNA-seq data into clusters based on the subgroups identified in the previous stage of the analysis and run DCM to identify sets of differentially correlated genes across subtypes. We will then investigate the gene sets to identify potential underlying biological mechanisms. Existing analyses focus on gene counts, and it is possible for counts to remain similar while correlations change. This is potentially interesting because differential correlation could indicate that a group of genes which normally work together aren't functioning together in the same way in a particular subtypes.

3.5 Survival Analysis

We will fit Kaplan-Meier Survival curves for each of the DNA damage response subtypes we identify to estimate the unadjusted difference in survival. Then we will fit a Cox proportional hazards model with the DNA damage response subtypes and clinical variables as predictors to estimate the effect of the DNA damage response subtypes on survival controlling for clinical factors like age. To better understand the predictive accuracy and the robustness of the model, we will split the data into training and test data sets using a 70/30 train/test split and report the prediction error on the test set.

3.6 Repair Pathway

If there are differences in survival between subgroups we will follow up to see which repair pathways are most important to drug response. This is an interesting question since people often assume repair is a mechanism of resistance to platinum but there really isn't any strong evidence for this.

3.7 Clustering by Immune Inhibitors

Time permitting, we will apply this same analysis pipeline to investigate immune inhibitors. Ideally this will only involve changing the gene list in subsection 3.2 and rerunning our analyses.

We know that there are synergistic effects between platinum and immune inhibitors but the relationship between these has not been fleshed out fully. We can cluster samples based on immune response related genes and then see if there is a difference in survival based on these. The follow-up we can look at which pathways may be associated with decreased response to platinum and see if there are drugs that modulate those. The original TCGA paper did define a subtype of ovarian cancer as "immune responsive" and we can compare if our clustering just sorts according to that subtype or if it suggests additional sub-subtypes.

References

- [1] Kelly Bodwin, Kai Zhang, and Andrew Nobel. A testing-based approach to the discovery of differentially correlated variable sets, 2016.
- [2] M. B. Eisen, P. T. Spellman, P. O. Brown, and D. Botstein. Cluster analysis and display of genome-wide expression patterns. *Proceedings of the National Academy of Sciences*, 95(25):14863–14868, December 1998.
- [3] Stefano Monti, Pablo Tamayo, Jill Mesirov, and Todd Golub. Consensus Clustering: A Resampling-Based Method for Class Discovery and Visualization of Gene Expression Microarray Data. *Machine Learning*, 52(1):91–118, July 2003.
- [4] Cancer Genome Atlas Research Network et al. Integrated genomic analyses of ovarian carcinoma. *Nature*, 474(7353):609, 2011.